CoChat
Sign Up
Cited by 14

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction

Correale, Michele, Mazzeo, Pietro, Tricarico, Lucia, Croella, Francesca, Fortunato, Martino, Magnesa, Michele, Amatruda, Marco, Alfieri, Simona, Ferrara, Salvatore, Ceci, Vincenzo, Dattilo, Giuseppe, Mele, Marco, Iacoviello, Massimo, Brunetti, Natale Daniele·2022·Clinical Drug Investigation
DOI 10.1007/s40261-022-01166-2
Open this paper in CoChat — free account

Abstract

Cardiac remodelling is an adverse phenomenon linked to heart failure progression and an important contributor to heart failure severity. Cardiac remodelling could represent the real therapeutic goal in the treatment of patients with heart failure with reduced ejection fraction, being potentially reversed through different pharmacotherapies. Currently, there are well-established drugs such as angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and β-blockers with anti-remodelling effects; recently, angiotensin receptor neprilysin inhibitor effects on inhibiting cardiac remodelling (improving N-terminal pro-B-type natriuretic peptide levels, echocardiographic parameters of reverse cardiac remodelling and right ventricular function in patients with heart failure with reduced ejection fraction) were demonstrated. More recently, hemodynamic consequences of gliflozins, reduced cardiac hydrostatic pressure as a possible cause of ventricular remodelling and hypertrophy were proposed to explain potential anti-remodelling effects of gliflozins. Gliflozins exert their cardioprotective effects by attenuating myofibroblast activity and collagen-mediated remodelling. Another postulated mechanism is represented by the reduction in sympathetic activity, through the reduction in renal afferent nervous activity and the suppression of central reflex mechanisms. Benefits of gliflozins on left ventricular hypertrophy, dilation, and systolic and diastolic function were also d…

Overview

Integrity signals

Registry

Crossref · 10.1007/s40261-022-01166-2

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 118

  1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling concepts and clinical implications: a consensus paper from an international forum of cardiac remodeling. J Am Coll Cardiol. 2000;35:569–82. · DOI · Paper page
  2. Tardif JC, O’Meara E, Komajda M, Böhm M, Borer JS, Ford I, SHIFT Investigators, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32:2507–15. · DOI · Paper page
  3. Correale M, Tricarico L, Fortunato M, Mazzeo P, Nodari S, Di Biase M, et al. New targets in heart failure drug therapy. Front Cardiovasc Med. 2021;8: 665797. · DOI
  4. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, ESC Scientific Document Group, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726. · DOI · Paper page
  5. Wu QQ, Xiao Y, Yuan Y, Ma ZG, Liao HH, Liu C, et al. Mechanisms contributing to cardiac remodeling. Clin Sci. 2017;24(131):2319–45. · DOI
  6. Schirone L, Forte M, Palmerio S, Yee D, Nocella C, Angelini F, et al. A review of the molecular mechanism underlying the development and progression of cardiac remodeling. Oxid Med Cell Longev. 2017;2017:3920195. · DOI
  7. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation. 2013;128:388–400. · DOI
  8. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature. 2011;469:323–35. · DOI · Paper page
  9. Dorn GW 2nd. Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc Res. 2009;81:465–73. · DOI
  10. Harvey PA, Leinwand LA. The cell biology of disease: cellular mechanisms of cardiomyopathy. J Cell Biol. 2011;194:355–65. · DOI
  11. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998;93:215–28. · DOI
  12. Lehnart SE, Maier LS, Hasenfuss G. Abnormalities of calcium metabolism and myocardial contractility depression in the failing heart. Heart Fail Rev. 2009;14:213–24. · DOI
  13. Chen K, Mehta JL, Li D, Joseph L, Joseph J. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res. 2004;95:1167–73. · DOI
  14. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis. Growth Factors. 2011;29:196–202. · DOI
  15. Mortensen RM. Immune cell modulation of cardiac remodeling. Circulation. 2012;125:1597–600. · DOI
  16. Segura AM, Frazier OH, Buja LM. Fibrosis and heart failure. Heart Fail Rev. 2014;19:173–85. · DOI
  17. Yu E, Mercer J, Bennett M. Mitochondria in vascular disease. Cardiovasc Res. 2012;95:173–82. · DOI
  18. Ikeuchi M, Matsusaka H, Kang D, Matsushima S, Ide T, Kubota T, et al. Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. Circulation. 2005;112:683–90. · DOI
  19. Neubauer S. The failing heart: an engine out of fuel. N Engl J Med. 2007;356:1140–51. · DOI
  20. Segers VFM, Brutsaert DL, De Keulenaer GW. Cardiac remodeling: endothelial cells have more to say than just NO. Front Physiol. 2018;9:382. · DOI
  21. Wang Y, Wang C, Ma J. Role of cardiac endothelial cells-derived microRNAs in cardiac remodeling. Discov Med. 2019;28:95–105.
  22. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4:98–108. · DOI
  23. Meng S, Zhu Y, Liu K, Jia R, Nan J, Chen M, et al. The stress hyperglycaemia ratio is associated with left ventricular remodelling after first acute ST-segment elevation myocardial infarction. BMC Cardiovasc Disord. 2021;21:72. · DOI
  24. Cokkinos DV, Belogianneas C. Left ventricular remodelling: a problem in search of solutions. Eur Cardiol. 2016;11:29–35. · DOI
  25. Ndrepepa G, Mehilli J, Martinoff S, Schwaiger M, Schömig A, Kastrati A. Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction. J Am Coll Cardiol. 2007;50:149–56. · DOI
  26. Aimo A, Fabiani I, Vergaro G, Arzilli C, Chubuchny V, Pasanisi EM, et al. Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. ESC Heart Fail. 2021;8:3014–25. · DOI
  27. Lupón J, Gaggin HK, de Antonio M, Domingo M, Galán A, Zamora E, et al. Biomarker-assist score for reverse remodeling prediction in heart failure: the ST2-R2 score. Int J Cardiol. 2015;184:337–43. · DOI
  28. Iwahashi N, Kirigaya J, Gohbara M, Abe T, Horii M, Hanajima Y, et al. Global strain measured by three-dimensional speckle tracking echocardiography is a useful predictor for 10-year prognosis after a first ST-elevation acute myocardial infarction. Circ J. 2021;85:1735–43. · DOI
  29. Park SM, Kim YH, Ahn CM, Hong SJ, Lim DS, Shim WJ. Relationship between ultrasonic tissue characterization and myocardial deformation for prediction of left ventricular reverse remodelling in non-ischaemic dilated cardiomyopathy. Eur J Echocardiogr. 2011;12:887–94. · DOI
  30. Marsan NA, Breithardt OA, Delgado V, Bertini M, Tops LF. Predicting response to CRT: the value of two- and three-dimensional echocardiography. Europace. 2008;10 Suppl. 3:iii13–9.
  31. Matthaei D, Haase A, Henrich D, Duhmke E. Cardiac and vascular imaging with an MR snapshot technique. Radiology. 1990;177:527–32. · DOI
  32. Vanhoutte L, Gerber BL, Gallez B, Po C, Magat J, Jean-Luc B, et al. High field magnetic resonance imaging of rodents in cardiovascular research. Basic Res Cardiol. 2016;111:1–20. · DOI · Paper page
  33. Weiger M, Pruessmann KP, Boesiger P. Cardiac real-time imaging using SENSE. Magn Reson Med. 2000;43:177–84. · DOI
  34. Kida K, Yoneyama K, Kobayashi Y, Takano M, Akashi YJ, Miyake F. Late gadolinium enhancement on cardiac magnetic resonance images predicts reverse remodeling in patients with nonischemic cardiomyopathy treated with carvedilol. Int J Cardiol. 2013;168:1588–9. · DOI
  35. Barison A, Aimo A, Ortalda A, Todiere G, Grigoratos C, Passino C, et al. Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. Int J Cardiol. 2018;250:195–200. · DOI
  36. Ota S, Orii M, Nishiguchi T, Yokoyama M, Matsushita R, Takemoto K, et al. Implications of multiple late gadolinium enhancement lesions on the frequency of left ventricular reverse remodeling and prognosis in patients with non-ischemic cardiomyopathy. J Cardiovasc Magn Reson. 2021;23:32. · DOI
  37. Xu Y, Li W, Wan K, Liang Y, Jiang X, Wang J, et al. Myocardial tissue reverse remodeling after guideline-directed medical therapy in idiopathic dilated cardiomyopathy. Circ Heart Fail. 2021;14: e007944. · DOI
  38. Barison A, Grigoratos C, Todiere G, Aquaro GD. Myocardial interstitial remodelling in nonischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance. Heart Fail Rev. 2015;20:731–49. · DOI
  39. Krzesinski JM, Rorive G, Cauwenberge V. Hypertension and left ventricular hypertrophy. Acta Cardiol. 1996;51:143–54.
  40. Curley D, Lavin Plaza B, Shah AM, Botnar RM. Molecular imaging of cardiac remodelling after myocardial infarction. Basic Res Cardiol. 2018;113:10. · DOI
  41. Jaarsma C, Leiner T, Bekkers SC, Crijns HJ, Wildberger JE, Nagel E, et al. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2012;59:1719–28. · DOI
  42. Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J. 2010;31:2984–95. · DOI
  43. Sayer G, Bhat G. The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin. 2014;32:21–32. · DOI
  44. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol. 2010;50:439–65. · DOI
  45. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 1997;95(5):1115–8. · DOI
  46. Reis Filho JR, Cardoso JN, Cardoso CM, Pereira-Barretto AC. Reverse cardiac remodeling: a marker of better prognosis in heart failure. Arq Bras Cardiol. 2015;104:502–6.
  47. Konstam MA, Rousseau MF, Kronenberg MW, Udelson JE, Melin J, Stewart D, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation. 1992;86:431–8. · DOI
  48. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669–77. · DOI · Paper page
  49. Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis. 2016;10:162–71. · DOI
  50. Ma Y, Yuan J, Hu J, Gao W, Zou Y, Ge J. ACE inhibitor suppresses cardiac remodeling after myocardial infarction by regulating dendritic cells and AT2 receptor-mediated mechanism in mice. Biomed Pharmacother. 2019;114: 108660. · DOI
  51. Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S, et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J. 2000;139:1081–7. · DOI
  52. Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362(9386):772–6. https://doi.org/10.1016/S0140-6736(03)14284-5 · DOI · Paper page
  53. Young MJ, Rickard AJ. Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals. J Endocrinol. 2015;224:R1-13. · DOI
  54. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689–97. · DOI
  55. Lother A, Moser M, Bode C, Feldman RD, Hein L. Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu Rev Pharmacol Toxicol. 2015;55:289–312. · DOI
  56. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350:266–72. · DOI
  57. López-Andrés N, Martin-Fernandez B, Rossignol P, Zannad F, Lahera V, Fortuno MA, et al. A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone. Am J Physiol Heart Circ Physiol. 2011;301:H2372–82. · DOI
  58. Martín-Fernández B, de las Heras N, Miana M, Ballesteros S, Delgado C, Song S, et al. Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression. J Cardiovasc Pharmacol. 2011;57:114–21. · DOI
  59. Tong M, Zablocki D, Sadoshima J. The role of Drp1 in mitophagy and cell death in the heart. J Mol Cell Cardiol. 2020;142:138–45. · DOI
  60. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301:H2181–90. · DOI
  61. Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013;113:739–53. · DOI
  62. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257–63. · DOI
  63. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol. 2003;14:2395–401. · DOI
  64. Parker BM, Wertz SL, Pollard CM, Desimine VL, Maning J, McCrink KA, et al. Novel insights into the crosstalk between mineralocorticoid receptor and G protein-coupled receptors in heart adverse remodeling and disease. Int J Mol Sci. 2018;19:3764. · DOI
  65. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17. · DOI · Paper page
  66. Pitt B, Remme W, Zannad F, Eplerenone Post-Acute Myocardial Infarction Efficacy and Survival Study Investigators, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21. · DOI · Paper page
  67. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, EMPHASIS-HF Study Group, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21. · DOI · Paper page
  68. Reiken S, Wehrens XH, Vest JA, Barbone A, Klotz S, Mancini D, et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation. 2003;107:2459–66. · DOI
  69. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Carvedilol Prospective Randomized Cumulative Survival Study Group, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;31(344):1651–8. · DOI · Paper page
  70. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7. · DOI
  71. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13. · DOI
  72. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101:865–9. · DOI
  73. Metra M, Nodari S, Dei CL. The role of beta blockade in heart failure. Eur Cardiol Rev. 2005;1(1):1–6. · DOI
  74. Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA. 2003;289(6):712–8. · DOI
  75. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266):1385–90. · DOI · Paper page
  76. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Carvedilol Or Metoprolol European Trial Investigators, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13. · DOI · Paper page
  77. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, SENIORS Investigators, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–25. · DOI
  78. Januzzi Jr JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al.; PROVE-HF Investigators. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019 Sep 17;322(11):1085–95. · DOI · Paper page
  79. Januzzi JL Jr, Camacho A, Piña IL, Rocha R, Williamson KM, Maisel AS, PROVE-HF Investigators, et al. Reverse cardiac remodeling and outcome after initiation of sacubitril/valsartan. Circ Heart Fail. 2020;13(6):e006946. · DOI
  80. Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, Caravaca-Pérez P, Conde-Martel A, Crespo-Leiro MG, et al. Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction: a review. Front Cardiovasc Med. 2021;11(8): 754499. · DOI
  81. Zile MR, O’Meara E, Claggett B, Prescott MF, Solomon SD, Swedberg K, et al. Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol. 2019;73(7):795–806. · DOI
  82. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, PARADIGM-HF Investigators and Committees, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. · DOI · Paper page
  83. Januzzi JL Jr, Prescott MF, Butler J, James L, Butler MF, J, et al. Effects of sacubitril/valsartan therapy on biomarkers, myocardial remodeling and outcomes (PROVE-HF). JAMA. 2019;322:1085–95. · DOI · Paper page
  84. Abboud A, Januzzi JL. Reverse cardiac remodeling and ARNI therapy. Curr Heart Fail Rep. 2021;18:71–83. · DOI
  85. Chen F, Tian G, Bai X, Li J, Yuan Z. The effect of sacubitril/valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction. Ann Palliat Med. 2021;10:8684–91. · DOI
  86. Paolini C, Mugnai G, Dalla Valle C, Volpiana A, Ferraglia A, Frigo AC, et al. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: a 24-month follow-up. Int J Cardiol Heart Vasc. 2021;35: 100821.
  87. Lee YH, Chiou WR, Hsu CY, Lin PL, Liang HW, Chung FP, et al. Different left ventricular remodeling patterns and clinical outcomes between non-ischemic and ischemic etiologies in heart failure patients receiving sacubitril/valsartan treatment. Eur Heart J Cardiovasc Pharmacother. 2022;8:118–29. · DOI
  88. Kim HM, Kim KH, Park JS, Oh BH. Beneficial effect of left ventricular remodeling after early change of sacubitril/valsartan in patients with nonischemic dilated cardiomyopathy. Medicina. 2021;57:416. · DOI
  89. Correale M, Mallardi A, Mazzeo P, Tricarico L, Diella C, Romano V, et al. Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: the Daunia Heart Failure Registry. Int J Cardiol Heart Vasc. 2020;27: 100486.
  90. Correale M, Mazzeo P, Magnesa M, Fortunato M, Tricarico L, Leopizzi A, et al. Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure. Clin Physiol Funct Imaging. 2021;41:505–13. · DOI
  91. Correale M, Mallardi A, Tricarico L, Mazzeo P, Ferraretti A, Diella C, et al. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan. Acta Cardiol. 2021;6:1–6. · DOI
  92. Docherty KF, Campbell RT, Brooksbank KJM, Dreisbach JG, Forsyth P, Godeseth RL, et al. Effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation. 2021;144:199–209. · DOI
  93. McMurray JJV, Solomon SD, Inzucchi SE, DAPA-HF Trial Committees and Investigators, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2200. · DOI · Paper page
  94. Bhatt DL, Verma S, Braunwald E. The DAP-HF trial: a momentous victory in the war against heart failure. Cell Metab. 2019;30:847–9. · DOI
  95. Neal B, Perkovic V, Mahaffey KW. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57. · DOI · Paper page
  96. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632–44. · DOI
  97. Wojcik C, Warden BA. Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors. Curr Cardiol Rep. 2019;21:130. · DOI
  98. Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, et al. Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results. Can J Cardiol. 2020;36:543–53. · DOI
  99. Li C, Zhang J, Xue M, Li X, Han F, Liu X, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. · DOI
  100. Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG. Sodium glucose transporter 2 (SGLT2) inhibition with empaglifozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16:9. · DOI
  101. Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G, et al. Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci. 2017;2:347–54. · DOI
  102. Connelly KA, Zhang Y, Desjardins JF, Nghiem L, Visram A, Batchu SN, et al. Load-independent effects of empaglifozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc Diabetol. 2020;19:13. · DOI
  103. Pabel S, Wagner S, Bollenberg H, Bengel P, Kovács Á, Schach C, Tirilomis P, Mustroph J, Renner A, Gummert J, Fischer T, Van Linthout S, Tschöpe C, Streckfuss-Bömeke K, Hasenfuss G, Maier LS, Hamdani N, Sossalla S. Empaglifozin directly improves diastolic function in human heart failure. Eur Heart J. 2018;39:284–5. · DOI
  104. Zhang N, Feng B, Ma X, Sun K, Xu G, Zhou Y. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2019;18:107. · DOI
  105. Shi L, Zhu D, Wang S, Jiang A, Li F. Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload. Am J Hypertens. 2019;32:452–9. · DOI
  106. Garcia-Ropero A, Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Picatoste B, Ishikawa K, et al. Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy. Expert Rev Cardiovasc Ther. 2020;18(9):635–42. · DOI
  107. Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. 2016;39:e212–3. · DOI
  108. Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of dapaglifozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41:3421–32. · DOI
  109. Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empaglifozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140:1693–702. · DOI
  110. Yu YW, Zhao XM, Wang YH, Zhou Q, Huang Y, Zhai M, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovasc Diabetol. 2021;20:25. · DOI
  111. Patoulias D, Papadopoulos C, Katsimardou A, Kalogirou M-S, Doumas M. Meta-analysis assessing the effect of sodium-glucose co-transporter-2 inhibitors on left ventricular mass patients with type 2 diabetes mellitus. Am J Cardiol. 2020;134:149–52. · DOI
  112. Singh JSS, Mordi IR, Vickneson K, Fathi A, Donnan PT, Mohan M, et al. Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM Trial. Diabetes Care. 2020;43:1356–9. · DOI
  113. Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143:516–25. · DOI
  114. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, EMPA-TROPISM (ATRU-4) Investigators, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77:243–55. · DOI
  115. Goldberg LR. The pleiotropic effects of SGLT2 inhibitors: remodeling the treatment of heart failure. J Am Coll Cardiol. 2021;77(3):256–8. · DOI
  116. Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl Sci. 2019;4(1):15–26. · DOI
  117. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384:105–16. · DOI · Paper page
  118. Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF Study. J Am Coll Cardiol. 2016;67:1444–55. · DOI

Cited by

Sorted by citations

Metadata

Authors
Correale, M., Mazzeo, P., Tricarico, L., Croella, F., Fortunato, M., Magnesa, M., Amatruda, M., Alfieri, S., Ferrara, S., Ceci, V., Dattilo, G., Mele, M., Iacoviello, M., & Brunetti, N. D.
Venue
Clinical Drug Investigation
Publisher
Springer Science and Business Media LLC
Published
2022-06-20
Volume
42
Issue
7
Pages
567-579
ISSN
  • 1173-2563
  • 1179-1918
DOI
10.1007/s40261-022-01166-2
Cited by
14
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review